Amyris, Inc. (AMRS) Bundle
A Brief History of Amyris, Inc. (AMRS)
Founding and Early Years
Founding and Early Years
Amyris, Inc. was founded in 2003 in Emeryville, California, as a spinoff from research conducted at the University of California, Berkeley. The company originally focused on the development of renewable alternatives to petroleum-based products.
Initial Public Offering (IPO)
In 2010, Amyris went public, trading on the NASDAQ under the ticker symbol AMRS. The IPO raised approximately $84 million.
Strategic Partnerships
Over the years, Amyris has established several strategic partnerships aimed at leveraging its technology platform. Notable collaborations include:
- With Total S.A. in 2014, which involved a $50 million investment to develop biofuels.
- In 2019, a collaboration with the Brazilian firm GranBio for the commercialization of renewable products.
Financial Performance
Amyris reported financial figures for the following fiscal years:
Year | Revenue (in millions) | Net Income (in millions) | Operating Expenses (in millions) |
---|---|---|---|
2018 | $27.3 | ($37.3) | $60.2 |
2019 | $34.0 | ($62.1) | $63.0 |
2020 | $36.5 | ($30.3) | $60.6 |
2021 | $59.3 | ($29.6) | $66.4 |
2022 | $130.0 | ($143.7) | $128.0 |
Recent Developments
As of 2023, Amyris has focused on consumer products and has expanded its portfolio to include clean beauty and wellness products. The company reported strong sales growth with an expected revenue target of $250 million for the fiscal year.
Market Capitalization and Stock Performance
As of October 2023, Amyris, Inc. had a market capitalization of approximately $306 million. The stock price has seen significant volatility, with a 52-week range of $0.65 to $4.21.
Sustainability Initiatives
Amyris prioritizes sustainability, utilizing innovative technology to produce ingredients used in cosmetics, fragrances, and other consumer products. The company reports that its renewable products can reduce greenhouse gas emissions by up to 90% compared to traditional petrochemical processes.
Future Outlook
Looking ahead, Amyris aims to continue expanding its product line and market reach while focusing on partnerships that enhance its position in the biochemistry industry. Analysts project an anticipated annual growth rate of 30% in the coming years.
A Who Owns Amyris, Inc. (AMRS)
Shareholder Composition
The ownership structure of Amyris, Inc. (AMRS) is diverse, comprising institutional investors, retail investors, and company insiders. As of the latest available data, the following table illustrates the major shareholders and their respective ownership percentages.
Shareholder Type | Shareholder Name | Ownership Percentage | Shares Owned |
---|---|---|---|
Institutional Investor | The Vanguard Group, Inc. | 9.1% | 11,600,000 |
Institutional Investor | BlackRock, Inc. | 8.5% | 10,900,000 |
Institutional Investor | State Street Corporation | 5.7% | 7,400,000 |
Insider | John Melo (CEO) | 2.2% | 2,800,000 |
Insider | Executive Management | 3.0% | 3,900,000 |
Retail Investor | Various | 71.5% | 91,500,000 |
Institutional Ownership
As of the end of Q3 2023, institutional investors hold a significant portion of Amyris, Inc.'s shares. The following statistics reflect their investment activity:
- Percentage of total shares held by institutions: 23.3%
- Total number of institutional shareholders: 150
- Average stake of large institutions: 5 million shares
Insider Ownership
Insider ownership remains crucial in influencing company decisions and performance. Key statistics regarding insider ownership are as follows:
- Percentage of shares held by insiders: 5.2%
- Total number of insider shareholders: 10
- Latest insider transactions in the past year: 5
Recent Stock Performance
The stock performance of Amyris, Inc. has been volatile over the past year. Relevant financial figures include:
- Current stock price: $1.52 (as of October 2023)
- 52-week high: $9.25
- 52-week low: $1.12
- Market capitalization: $356 million
Key Financial Metrics
In assessing the company's economic health and performance, the following key financial metrics are pertinent:
Metric | Value |
---|---|
Revenue (2022) | $66 million |
Net Income (2022) | ($145 million) |
Operating Expenses (2022) | $163 million |
Total Assets (Q2 2023) | $542 million |
Total Liabilities (Q2 2023) | $350 million |
Summary of Ownership Trends
Understanding the ownership trends can provide insights into the company's strategic direction. The recent trends include:
- Increase in institutional investment over the last year: 5%
- Insider selling activity noted in Q3 2023
- Retail ownership remains the dominant force, accounting for over 70% of shares
Amyris, Inc. (AMRS) Mission Statement
Company Overview
Company Overview
Amyris, Inc. (AMRS) is a biotechnology firm based in Emeryville, California, focusing on sustainable products. The company leverages its synthetic biology platform to produce renewable ingredients across various markets, including personal care, nutrition, and pharmaceuticals.
Mission Statement
The mission of Amyris, Inc. is to "deliver sustainable, high-quality products that improve the quality of life for people around the world." This statement underlines the company's commitment to innovation, sustainability, and health.
Core Values
- Innovation: Pioneering new technologies in biotechnology.
- Sustainability: Prioritizing eco-friendly production methods.
- Quality: Ensuring high standards in product offerings.
- Collaboration: Working with partners to achieve common goals.
- Integrity: Upholding ethical standards in all business practices.
Market Focus
Amyris primarily targets three sectors:
- Personal Care: Ingredients for cosmetics and skincare.
- Nutrition: Health supplements and alternative sweeteners.
- Pharmaceuticals: Active pharmaceutical ingredients (APIs).
Financial Performance
Year | Revenue (in million USD) | Net Income (in million USD) | Market Capitalization (in million USD) |
---|---|---|---|
2021 | 70.8 | (66.4) | 735.5 |
2022 | 109.8 | (29.5) | 813.7 |
2023 | 145.3 (estimated) | (12.1) (estimated) | 873.9 (estimated) |
Recent Developments
In 2023, Amyris has made significant strides in its product line:
- Launch of a new plant-based sweetener: Projected to bring in $45 million in revenue.
- Partnership with major cosmetic brands: Expected to enhance market penetration.
- Expansion of production facilities: Aiming for a 30% increase in output by 2024.
Sustainability Initiatives
Amyris is committed to reducing its carbon footprint by:
- Utilizing renewable energy: Aim for 100% renewable power by 2025.
- Reducing waste: Targeting a 50% decrease in manufacturing waste.
- Sourcing sustainable materials: All raw materials by 2025 will be sustainably sourced.
Conclusion
Amyris continues to innovate within the biotechnology sector, maintaining a strong commitment to sustainability and quality in line with its mission statement.
How Amyris, Inc. (AMRS) Works
Business Model
Amyris, Inc. operates as a biotechnology company focused on the development and production of sustainable ingredients derived from renewable resources. The company's innovative platform integrates advanced science and biotechnology to convert sugarcane into high-value ingredients for health and wellness, personal care, and industrial applications.
Revenue Streams
Amyris has diversified its revenue streams primarily through:
- Consumer Products: Developing and selling branded products directly to consumers.
- B2B Partnerships: Collaborating with companies across various sectors, providing them with high-performance ingredients.
- Licensing Agreements: Licensing its technology to other manufacturers.
Financial Performance
As of the third quarter of 2023, Amyris reported the following financial metrics:
Metric | Amount (in millions) |
---|---|
Revenue | $83.8 |
Net Income (Loss) | $(70.7) |
Gross Margin | 34% |
Total Assets | $300.5 |
Total Liabilities | $250.6 |
Cash and Cash Equivalents | $56.7 |
Market Position
Amyris, Inc. has carved out a niche in the sustainable ingredients market, competing primarily in the following sectors:
- Personal Care: Ingredients for skincare and cosmetic products.
- Nutrition: Products such as sweeteners and nutritional ingredients.
- Industrial Applications: Sustainable alternatives for traditional petrochemicals.
Research and Development
Investment in research and development is critical to Amyris’ strategy, with R&D expenditures reported at:
Year | R&D Expenditure (in millions) |
---|---|
2020 | $25.3 |
2021 | $30.7 |
2022 | $32.1 |
2023 (projected) | $35.0 |
Strategic Partnerships
Amyris has established multiple strategic partnerships to enhance its operational capabilities:
- Partnership with BASF: Focused on joint development of ingredients for various sectors.
- Collaboration with DSM: Targeting health and nutrition solutions.
- Alliances with Consumer Brands: Co-developing products that leverage Amyris' technology.
Sustainability Initiatives
Amyris emphasizes sustainability in its operations, aiming for a reduced carbon footprint. The company's commitment includes:
- Renewable Resources: Utilizing sugarcane for ingredient production.
- Carbon Negative Operations: Targeting carbon-negative across their supply chain.
- Transparent Supply Chains: Reporting sustainability metrics regularly.
Future Outlook
Amyris projects continued growth in various markets, with estimated revenue targets for 2024 set at around $120 million, leveraging advances in biotechnology for new product launches.
How Amyris, Inc. (AMRS) Makes Money
Revenue Streams
Amyris, Inc. primarily generates revenue through several key segments:
- Consumer Products
- Ingredients for Health & Nutrition
- Ingredients for Personal Care
- Industrial Products
- Partnerships and Collaborations
Consumer Products
The consumer products segment includes brands like Biossance and Purecane. In Q2 2023, Amyris reported consumer product sales amounting to $17.3 million, a significant increase from the previous year.
Ingredients for Health & Nutrition
Amyris supplies high-quality ingredients for health and nutrition, including sweeteners and active pharmaceutical ingredients. The revenue in this segment was approximately $16.5 million in 2022.
Ingredients for Personal Care
This segment contributed around $14.8 million to the total revenue in the fiscal year 2022, driven by the demand for sustainable ingredients in skincare and cosmetics.
Industrial Products
Amyris also focuses on producing industrial biochemicals. In 2022, this segment generated revenues of $20 million, mainly from biobased chemicals used in various applications.
Partnerships and Collaborations
Amyris engages in partnerships with global companies to expand its reach. In 2023, collaborations with companies such as TotalEnergies contributed an estimated $15 million in revenue.
Financial Performance
In the fiscal year 2022, Amyris reported total revenues of $73.2 million, reflecting a year-over-year increase of approximately 40%.
Revenue Breakdown
Segment | Revenue (2022) | Percentage of Total Revenue |
---|---|---|
Consumer Products | $17.3 million | 23.6% |
Health & Nutrition | $16.5 million | 22.5% |
Personal Care | $14.8 million | 20.2% |
Industrial Products | $20 million | 27.3% |
Partnership Revenues | $15 million | 20.5% |
Cost Structure
Amyris's cost structure consists of several components, including:
- Research and Development (R&D)
- Manufacturing Costs
- Marketing and Sales Expenses
- Administrative Costs
Research and Development (R&D)
R&D expenses for Amyris were approximately $25 million in 2022, reflecting investment in biotechnology innovation and product development.
Manufacturing Costs
The total manufacturing cost was reported at about $18 million in 2022, associated with the production of biochemicals and consumer products.
Marketing and Sales Expenses
These expenses were around $12 million in 2022, highlighting the company's focus on brand promotion and market expansion.
Administrative Costs
Amyris incurred administrative costs totaling approximately $10 million in the same period, related to corporate functions and operational management.
Financial Metrics
As of Q2 2023, Amyris had a market capitalization of approximately $588 million. The company's net loss for the same quarter was reported at $13 million.
Stock Performance
As of October 2023, the stock price of AMRS was approximately $1.40, with a year-to-date performance reflecting a decline of around 50%.
Future Revenue Projections
Analysts project that Amyris's revenue could reach approximately $100 million by 2025, driven by expanding market opportunities in sustainable products.
Amyris, Inc. (AMRS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support